The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
Abstract
CONTEXT: Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes. OBJECTIVE: To determine if the risk of serious cardiovascular harm is increased by rosiglitazone compared with pioglitazone, the other thiazolidinedione marketed in the United States. DESIGN, SETTING, AND PATIENTS: Nationwide, observational, retrospective, inception cohort of 227,571 Medicare beneficiaries aged 65 years or older (mean age, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who underwent follow-up for up to 3 years after thiazolidinedione initiation. MAIN OUTCOME MEASURES: Individual end points of acute myocardial infarction (AMI), stroke, heart failure, and all-cause mortality (death), and composite end point of AMI, stroke, heart failure, or death, assessed using incidence rates by thiazolidinedione, attributable risk, number needed to harm, Kaplan-Meier plots of time to event, and Cox proportional hazard ratios for time to event, adjusted for potential confounding factors, with pioglitazone as reference. RESULTS: A total of 8667 end points were observed during the study period. The adjusted hazard ratio for rosiglitazone compared with pioglitazone was 1.06 (95% confidence interval [CI], 0.96-1.18) for AMI; 1.27 (95% CI, 1.12-1.45) for stroke; 1.25 (95% CI, 1.16-1.34) for heart failure; 1.14 (95% CI, 1.05-1.24) for death; and 1.18 (95% CI, 1.12-1.23) for the composite of AMI, stroke, heart failure, or death. The attributable risk for this composite end point was 1.68 (95% CI, 1.27-2.08) excess events per 100 person-years of treatment with rosiglitazone compared with pioglitazone. The corresponding number needed to harm was 60 (95% CI, 48-79) treated for 1 year. CONCLUSION: Compared with prescription of pioglitazone, prescription of rosiglitazone was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“The proportional hazards assumption was assessed using a test of weighted Schoenfeld residuals.(32) The number needed to harm was estimated using the attributable risk.”
MethodEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 4×
“We restricted the cohorts to the 110 950 patients who entered the study prior to the May 21, 2007, publication of the rosiglitazone meta-analysis by Nissen and Wolski.(1) Nearly identical results were obtained for the main analysis (eTable 1, available at http://www .”
BackgroundMethodResultInfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Zipes, D. P., & Wellens, H. J. J. (1998) · Circulation · doi:10.1161/01.cir.98.21.2334 · Cited by 2,744
Sudden Cardiac Death in the United States, 1989 to 1998
Zheng, Z.-J., Croft, J. B., Giles, W. H., & Mensah, G. A. (2001) · Circulation · doi:10.1161/hc4301.098254 · Cited by 1,596
Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors
Birman-Deych, E., Waterman, A. D., Yan, Y., Nilasena, D. S., Radford, M. J., & Gage, B. F. (2005) · Medical Care · doi:10.1097/01.mlr.0000160417.39497.a9 · Cited by 719
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Kokotailo, R. A., & Hill, M. D. (2005) · Stroke · doi:10.1161/01.str.0000174293.17959.a1 · Cited by 709
Validating Administrative Data in Stroke Research
Tirschwell, D. L., & Longstreth, W. T. (2002) · Stroke · doi:10.1161/01.str.0000032240.28636.bd · Cited by 658
Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding
Mamdani, M., Sykora, K., Li, P., Normand, S.-L. T., Streiner, D. L., Austin, P. C., Rochon, P. A., & Anderson, G. M. (2005) · BMJ · doi:10.1136/bmj.330.7497.960 · Cited by 646
Kiyota, Y., Schneeweiss, S., Glynn, R. J., Cannuscio, C. C., Avorn, J., & Solomon, D. H. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.02.013 · Cited by 531
Austin, P. C., Daly, P. A., & Tu, J. V. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123839 · Cited by 525
Jong, P., Gong, Y., Liu, P. P., Austin, P. C., Lee, D. S., & Tu, J. V. (2003) · Circulation · doi:10.1161/01.cir.0000080290.39027.48 · Cited by 240
Petersen, L. A., Wright, S., Normand, S.-L. T., & Daley, J. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.10198.x · Cited by 233
Goff, D. C., Pandey, D. K., Chan, F. A., Ortiz, C., & Nichaman, M. Z. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.2.197 · Cited by 222
Roumie, C. L., Mitchel, E., Gideon, P. S., Varas‐Lorenzo, C., Castellsague, J., & Griffin, M. R. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1518 · Cited by 192
Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction.
Levy, A., Tamblyn, R. M., FITCHETT, D. H., McLeod, P. J., & Hanley, J. A. (1999) · PubMed · Cited by 191
Juurlink, D. N., Gomes, T., Lipscombe, L. L., Austin, P. C., Hux, J. E., & Mamdani, M. M. (2009) · BMJ · doi:10.1136/bmj.b2942 · Cited by 170
Hill, M. E., & Rosenwaike, I. (2001) · PubMed · Cited by 145
Winkelmayer, W. C., Setoguchi, S., Levin, R., & Solomon, D. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2368 · Cited by 125
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0090-3 · Cited by 123
Brownstein, J. S., Murphy, S. N., Goldfine, A. B., Grant, R. W., Sordo, M., Gainer, V. S., Colecchi, J., Dubey, A. K., Nathan, D. M., GLASER, J. P., et al. (2009) · Diabetes Care · doi:10.2337/dc09-1506 · Cited by 85
Gerrits, C. M., Bhattacharya, M., Manthena, S. R., Baran, R. W., Perez, A., & Kupfer, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1470 · Cited by 82
Hennessy, S., Leonard, C. E., Palumbo, C. M., Newcomb, C., & Bilker, W. B. (2007) · Medical Care · doi:10.1097/mlr.0b013e318148435a · Cited by 70
Predictors of Long-Term (4-year) Mortality in Elderly and Young Patients with Acute Heart Failure
Barsheshet, A., Shotan, A., Cohen, E., Garty, M., Goldenberg, I., Sandach, A., Behar, S., Zimlichman, E., Lewis, B. S., & Gottlieb, S. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq079 · Cited by 66
Habib, Z. A., Tzogias, L., Havstad, S. L., Wells, K. E., Divine, G., Lanfear, D. E., Tang, J. M., Krajenta, R. J., Pladevall, M., & Williams, L. K. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1722 · Cited by 53
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
A computer case definition for sudden cardiac death
Chung, C. P., Murray, K. T., Stein, C. M., Hall, K., & Ray, W. A. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1888 · Cited by 52
An algorithm to identify incident myocardial infarction using Medicaid data
Choma, N. N., Griffin, M. R., Huang, R. L., Mitchel, E. F., Kaltenbach, L. A., Gideon, P. S., Stratton, S. M., & Roumie, C. L. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1821 · Cited by 46
Ziyadeh, N. J., McAfee, A. T., Koro, C. E., Landon, J. E., & Chan, K. A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.003 · Cited by 44
Cited by
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488
“By contrast, thiazolidinediones are associated with weight gain, fluid retention and heart failure, and rosiglitazone has been associated with an increased risk of myocardial infarction”
BackgroundType 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
“Their conclusion was based on recent observational data (42, 43) and 2 meta-analyses by Nissen and Wolski (44, 45), as well as on increased understanding of the pharmacology of rosiglitazone (46).”
BackgroundNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
Metadata
- Authors
- Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., & Kelman, J. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-07-28
- Volume
- 304
- Issue
- 4
- Pages
- 411
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1998418707
- Cited by
- 512
- References
- 32
- FWCI
- 55.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.